These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1149 related items for PubMed ID: 19095852

  • 21. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B.
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT.
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A, Lauterio TJ, Davis MW.
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [Abstract] [Full Text] [Related]

  • 27. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM, Levitt JA.
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM, Curry JA.
    Tort Trial Insur Pract Law J; 2007 Feb; 43(1):35-70. PubMed ID: 18354866
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. FDA law enforcement: critical to product safety.
    Rados C.
    FDA Consum; 2006 Apr 09; 40(1):21-7. PubMed ID: 16528823
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Drug-review deadlines and safety problems.
    Carpenter D, Zucker EJ, Avorn J.
    N Engl J Med; 2008 Mar 27; 358(13):1354-61. PubMed ID: 18367738
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.